Dr. Usha S. Perepu, MBBS
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 77
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IA license 41239 -
Internal Medicine Physician
IA license 41239
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Health System San Antonio, TX
- Ut Health San Antonio Multispecialty & Research Ho San Antonio, TX
Medical groups
- University of Texas Health Science Center at San Antonio (1,297 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 77
- Services billed
- 164
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 85 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 31 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fondaparinux Sodium | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 42 payments worth $47,678 in total to this clinician.
| Genzyme Corporation | $30,416 |
|---|---|
| Agios Pharmaceuticals, Inc. | $17,239 |
| Blueprint Medicines Corporation | $22.40 |
| Consulting Fee | $24,650 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $16,718 |
| Travel and Lodging | $4,757 |
| Food and Beverage | $1,553 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 16, 2025 | Consulting Fee QFITLIA | $9,030 |
| Genzyme Corporation Aug 15, 2025 | Consulting Fee ALTUVIIIO · Hematology | $7,525 |
| Agios Pharmaceuticals, Inc. Jun 10, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $6,660 |
| Genzyme Corporation Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $4,888 |
| Agios Pharmaceuticals, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) PYRUKYND · Genetically Defined Disease | $4,715 |
| Genzyme Corporation Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,300 |
| Agios Pharmaceuticals, Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) PYRUKYND · Genetically Defined Disease | $1,940 |
| Genzyme Corporation Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $1,150 |
| Genzyme Corporation Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $1,150 |
| Agios Pharmaceuticals, Inc. Jul 3, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $833 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) PYRUKYND · Genetically Defined Disease | $1,940 |
| Agios Pharmaceuticals, Inc. Dec 11, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Houston, TX, TX | $539 |
| Agios Pharmaceuticals, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) PYRUKYND · Genetically Defined Disease | $4,715 |
| Agios Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Bellevue, WA | $551 |
| Agios Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Bellevue, WA | $233 |
| Agios Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Bellevue, WA | $214 |
| Genzyme Corporation Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $4,888 |
| Genzyme Corporation Sep 25, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Austin, TX | $112 |
| Genzyme Corporation Sep 25, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Austin, TX | $33.34 |
| Genzyme Corporation Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $1,150 |
| Genzyme Corporation Aug 15, 2025 | Consulting Fee ALTUVIIIO · Hematology | $7,525 |
| Genzyme Corporation Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $575 |
| Genzyme Corporation Aug 15, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to New Orleans, LA · in-kind | $383 |
| Genzyme Corporation Aug 15, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to New Orleans, LA · in-kind | $381 |
| Genzyme Corporation Aug 15, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to New Orleans, LA · in-kind | $153 |
| Genzyme Corporation Aug 15, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to New Orleans, LA | $88.31 |
| Agios Pharmaceuticals, Inc. Jul 3, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $833 |
| Agios Pharmaceuticals, Inc. Jun 18, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Los Angeles, CA | $144 |
| Agios Pharmaceuticals, Inc. Jun 10, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $6,660 |
| Genzyme Corporation May 29, 2025 | Consulting Fee | $602 |
| Agios Pharmaceuticals, Inc. May 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Los Angeles, CA | $814 |
| Agios Pharmaceuticals, Inc. May 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Los Angeles, CA | $227 |
| Genzyme Corporation May 16, 2025 | Consulting Fee QFITLIA | $9,030 |
| Genzyme Corporation May 16, 2025 | Travel and Lodging QFITLIA · travel to Cambridge, MA · in-kind | $537 |
| Genzyme Corporation May 16, 2025 | Travel and Lodging QFITLIA · travel to Cambridge, MA · in-kind | $313 |
| Genzyme Corporation May 16, 2025 | Travel and Lodging QFITLIA · travel to Cambridge, MA | $33.29 |
| Genzyme Corporation Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,300 |
| Genzyme Corporation Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $1,150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $49,563 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Genzyme Corporation · Recruiting · NCT07086976 - Goal Attainment and Physical Activity in People With Hemophilia A
Sanofi US Services Inc. · Terminated · NCT06530030 - A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia P…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.